Haemonetics HAE Turnaround costs

Discontinued — last reported Q4 '21

Segments

Blood Center$0-100%

Hospital$0-100%

Plasma$0-100%

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Market cap$3.31B-18.0%

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept hae:RestructuringRelatedCosts.

The official record: Haemonetics’s 10-K, filed May 26, 2021, on SEC EDGAR. View the filing →